pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 39 Non-oncology: 22
Oncology: 17
Under Consideration for Negotiation 21 Non-oncology: 11
Oncology: 10
Completed Negotiations 895 With Letter of Intent: 773
Without agreement: 122
Negotiations That Were Not Pursued 113

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Epuris Cipher Acne Vulgaris
Rebyota Ferring Canada Inc. Clostridioides difficile infection, prevention
Lyvdelzi Gilead Sciences Canada Inc. For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA.
Quviviq Idorsia Pharmaceuticals Canada Ltd. Insomnia
Alyftrek Vertex Pharmaceuticals (Canada) Incorporated Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older
Perjeta Hoffmann-La Roche Ltd. In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer
Ranvu Apotex Inc. Multiple Indications
Carvykti Janssen Inc. For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
Carvykti Janssen Inc. (du) Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Venclexta AbbVie Corporation Calquence, in combination with venetoclex, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)
Calquence AstraZeneca Canada Inc. Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.
Verzenio Eli Lilly Canada Inc. For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disea
Verzenio Eli Lilly Canada Inc. For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.
Talvey Janssen Inc. For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrat

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, who
Darzalex SC Janssen Inc. in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Lazcluze and Rybrevant Janssen Inc. For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR)

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Ofev Boehringer Ingelheim (Canada) Ltd. Idiopathic pulmonary fibrosis and PF-ILD
Spevigo Boehringer Ingelheim (Canada) Ltd. generalized pustular psoriasis (GPP)

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks